Tags

Type your tag names separated by a space and hit enter

iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
Curr Med Res Opin. 2017 12; 33(12):2187-2194.CM

Abstract

BACKGROUND

Achieving and maintaining glycemic control is important for people with type 2 diabetes (T2D), to reduce disease-related complications and mortality; however, about half of US patients fail to meet glycemic targets. iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide for once-daily administration, was recently approved by the US Food and Drug Administration for use in adults with T2D inadequately controlled on basal insulin (<60 U daily) or lixisenatide. iGlar and lixisenatide have complementary mechanisms of action, primarily targeting fasting plasma glucose and postprandial plasma glucose, respectively. In the US, iGlarLixi is available in a 3:1 ratio of iGlar and lixisenatide, respectively, across the dosage range of 15-60 U of iGlar and 5-20 µg of lixisenatide.

METHODS

This study identified phase 3 trials which assessed the efficacy and safety of iGlarLixi. Relevant trials were LixiLan-O, which compared iGlarLixi with iGlar or lixisenatide alone in insulin-naïve patients, and LixiLan-L, which compared iGlarLixi with iGlar alone in insulin-experienced patients.

RESULTS

Patients on iGlarLixi experienced greater A1C reduction and were more likely to achieve A1C <7.0% than its comparators. iGlarLixi mitigated the weight gain associated with iGlar without increasing hypoglycemia risk, and resulted in a lower frequency of gastrointestinal adverse events compared with lixisenatide.

CONCLUSIONS

iGlarLixi provides a new approach to therapy intensification in patients with T2D. iGlarLixi showed greater A1C efficacy compared with either iGlar or lixisenatide, mitigating iGlar-associated weight gain, without increasing hypoglycemia risk, and reducing the gastrointestinal side-effects seen with lixisenatide.

Authors+Show Affiliations

a Abington Family Medicine , Jenkintown , PA , USA. b Abington Jefferson Health , Jenkintown , PA , USA.b Abington Jefferson Health , Jenkintown , PA , USA.c University of North Dakota School of Medicine and Health Sciences , Grand Forks , ND , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28741967

Citation

Skolnik, Neil, et al. "IGlarLixi, a Titratable Once-daily Fixed-ratio Combination of Basal Insulin and Lixisenatide for Intensifying Type 2 Diabetes Management for Patients Inadequately Controlled On Basal Insulin With or Without Oral Agents." Current Medical Research and Opinion, vol. 33, no. 12, 2017, pp. 2187-2194.
Skolnik N, Dupree RS, Johnson EL. IGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Curr Med Res Opin. 2017;33(12):2187-2194.
Skolnik, N., Dupree, R. S., & Johnson, E. L. (2017). IGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Current Medical Research and Opinion, 33(12), 2187-2194. https://doi.org/10.1080/03007995.2017.1359518
Skolnik N, Dupree RS, Johnson EL. IGlarLixi, a Titratable Once-daily Fixed-ratio Combination of Basal Insulin and Lixisenatide for Intensifying Type 2 Diabetes Management for Patients Inadequately Controlled On Basal Insulin With or Without Oral Agents. Curr Med Res Opin. 2017;33(12):2187-2194. PubMed PMID: 28741967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. AU - Skolnik,Neil, AU - Dupree,Renell S, AU - Johnson,Eric L, Y1 - 2017/08/04/ PY - 2017/7/26/pubmed PY - 2018/5/2/medline PY - 2017/7/26/entrez KW - Fixed-ratio combination KW - GLP-1 receptor agonist KW - iGlarLixi KW - type 2 diabetes SP - 2187 EP - 2194 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 33 IS - 12 N2 - BACKGROUND: Achieving and maintaining glycemic control is important for people with type 2 diabetes (T2D), to reduce disease-related complications and mortality; however, about half of US patients fail to meet glycemic targets. iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide for once-daily administration, was recently approved by the US Food and Drug Administration for use in adults with T2D inadequately controlled on basal insulin (<60 U daily) or lixisenatide. iGlar and lixisenatide have complementary mechanisms of action, primarily targeting fasting plasma glucose and postprandial plasma glucose, respectively. In the US, iGlarLixi is available in a 3:1 ratio of iGlar and lixisenatide, respectively, across the dosage range of 15-60 U of iGlar and 5-20 µg of lixisenatide. METHODS: This study identified phase 3 trials which assessed the efficacy and safety of iGlarLixi. Relevant trials were LixiLan-O, which compared iGlarLixi with iGlar or lixisenatide alone in insulin-naïve patients, and LixiLan-L, which compared iGlarLixi with iGlar alone in insulin-experienced patients. RESULTS: Patients on iGlarLixi experienced greater A1C reduction and were more likely to achieve A1C <7.0% than its comparators. iGlarLixi mitigated the weight gain associated with iGlar without increasing hypoglycemia risk, and resulted in a lower frequency of gastrointestinal adverse events compared with lixisenatide. CONCLUSIONS: iGlarLixi provides a new approach to therapy intensification in patients with T2D. iGlarLixi showed greater A1C efficacy compared with either iGlar or lixisenatide, mitigating iGlar-associated weight gain, without increasing hypoglycemia risk, and reducing the gastrointestinal side-effects seen with lixisenatide. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/28741967/iGlarLixi_a_titratable_once_daily_fixed_ratio_combination_of_basal_insulin_and_lixisenatide_for_intensifying_type_2_diabetes_management_for_patients_inadequately_controlled_on_basal_insulin_with_or_without_oral_agents_ L2 - http://www.tandfonline.com/doi/full/10.1080/03007995.2017.1359518 DB - PRIME DP - Unbound Medicine ER -